Explore Products
Tumor Cell Lines

HT-55

  • BSL

    1

  • 415
Human colon carcinoma. Human colon epithelial cell line.
Request Your Custom Quote Today

Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.

Get a Quote
  • High Purity Levels
  • Precision and Reliability
  • Customization Options
Product Code

HT55

Species

Human

Cat.No

ABC-TC0431

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Cell Type

Epithelial

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Rectum

Disease

Rectal Adenocarinoma

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Colon Cancer Cell Lines

Description

HT-55 The HT-55 is a human colon cancer cell line derived from the rectum of a 54-year-old white female patient with rectal adenocarcinoma. The cells display well-differentiated cancer morphology and grow in adherent clumps that resemble columnar epithelium with a clear border. These clumps show an island growth pattern, forming multiple layers at the center. HT-55 cells retain certain intestinal epithelial functional characteristics, including the expression of epithelial cell polarity-related proteins, but their specific secretory functions have not yet been fully elucidated. As a rectal adenocarcinoma model, this cell carries multiple colorectal cancer characteristic gene mutations: APC gene (p.Gln1131Ter, p.Gln1303Ter, p.Arg1463Ser), TP53 gene (p.Arg213Leu), BRAF gene (p.Asn581Tyr) and DNMT3A gene (p.Lys241Ter), etc. These mutation spectra make it an ideal model for studying the pathogenesis and targeted therapy of colorectal cancer.

View Product Image

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Application

  • HT-55 is a valuable model for studying potential therapies for human rectal cancer. In studies involving HT-55, cell proliferation and death can be affected by anti-cancer drugs through the ERK 1/2, p38-MAPK, and PI3K/AKT pathways of ERK 1/2, p38-MARK, and PI3K/AKT. Further investigation can explore the utilization of existing anti-cancer therapy targeting these pathways in HT-55. Moreover, a BRAF mutation (N581Y) has been detected in HT-55, indicating that HT-55 can help improve strategies combining anti-EGFR monoclonal antibodies with BRAF inhibitors for BRAF mutant cancers to elucidate the molecular pathogenesis of colorectal cancer.

Inquiring HT-55

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button